When the analysis was restricted to the four trials that included patients with diabetic kidney disease, the placebo-subtracted reduction in the risk of CKD progression with SGLT-2 inhibitors was 40% (RR: 0.60; 95% CI: 0.53–0.69). Here, SLC5A2 is linked to chronic kidney disease.